YOUR SEARCH FOR Text 43 RESULTS
1 of Total
Understanding Diffuse Large B-cell Lymphoma (DLBCL) | Incyte Stories
… September 14, 2023 Understanding Diffuse Large B-cell Lymphoma (DLBCL) A blood cancer diagnosis, …
2 of Total
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a
… View all news Incyte Announces Positive Topline Results from … as a First-line Treatment for Diffuse Large B-Cell Lymphoma January 5, 2026 at 7:30 AM EST PDF …
3 of Total
Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… View all news Incyte Reports 2021 Third Quarter Financial Results … 2 (AGAVE-201) 1 Development collaboration with Cellenkos, Inc. 2 Clinical development of …
4 of Total
Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… View all news Incyte Reports 2021 Second Quarter Financial Results … with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) - Phase 3 TRuE-V1 and …
5 of Total
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… View all news Incyte Reports 2022 First Quarter Financial Results … for Incyte and the U.S. launch is off to an excellent start with over 38,000 patients treated …
6 of Total
Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guida
… View all news Incyte Reports 2021 Fourth Quarter and Year-End … in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in Europe ; and, in the …
7 of Total
Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… View all news Incyte Reports 2023 First Quarter Financial Results … evaluating ruxolitinib BID in combination with Cellenkos' CK0804 in MF is continuing to recruit …
8 of Total
Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… View all news Incyte Reports 2021 First Quarter Financial Results … (GRAVITAS-309) Development collaboration with Cellenkos, Inc. Clinical development of …
9 of Total
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… View all news Incyte Reports 2022 Second Quarter Financial Results … is March 23, 2023 . Incyte’s partner, Cellenkos, announced the FDA clearance of its …
10 of Total
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… View all news Incyte Reports 2023 Second Quarter Financial Results … evaluating ruxolitinib BID in combination with Cellenkos' CK0804 in MF is continuing to recruit …